Premium
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model
Author(s) -
Aliu S.O.,
Wilmes L.J.,
Moasser M.M.,
Hann B.C.,
Li K.L.,
Wang D.,
Hylton N.M.
Publication year - 2009
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.21737
Subject(s) - gefitinib , medicine , chemotherapy , tyrosine kinase inhibitor , breast cancer , nuclear medicine , urology , oncology , cancer research , cancer , epidermal growth factor receptor
Purpose To evaluate whether quantitative MRI parameters are sensitive to the effects of the tyrosine kinase inhibitor gefitinib and can discriminate between two different treatment protocols. Materials and Methods Untreated mice with BT474 breast tumor xenografts were characterized in a preliminary study. Subsequently, tumor volume, apparent diffusion coefficient (ADC), transendothelial permeability (K ps ), and fractional plasma volume (fPV) were measured in three groups of mice receiving: 1) control vehicle for 10 days, or gefitinib as 2) a single daily dose for 10 days or 3) a 2‐day pulsed dose. Results Gefitinib treatment resulted in significant tumor growth inhibition (pulsed: 439 ± 93; daily: 404 ± 53; control: 891 ± 174 mm 3 , P < 0.050) and lower cell density (pulsed: 0.15 ± 0.01, daily: 0.17 ± 0.01, control: 0.24 ± 0.01, P < 0.050) after 9 days. Tumor ADC increased in treated groups but decreased in controls ( P > 0.050). Tumor K ps decreased with pulsed treatment but rebounded afterwards and increased with daily treatment ( P > 0.050). Tumor fPV increased in both treated groups, decreasing afterwards with pulsed treatment ( P > 0.050). Conclusion Quantitative MRI can provide a sensitive measure of gefitinib‐induced tumor changes, potentially distinguish between treatment regimens, and may be useful for determining optimal treatment scheduling for enhancing chemotherapy delivery. J. Magn. Reson. Imaging 2009;29:1071–1079. © 2009 Wiley‐Liss, Inc.